InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.055

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$17 Change of Director's Interest Notice - PM 19 Jun 2023 7:06PM $0.058 $0.055 fallen by 5.17%
$17 Details of Company Address 19 Jun 2023 10:50AM $0.060 $0.055 fallen by 8.33%
$17 IONIC Trial Abstract Published at ASCO 26 May 2023 8:20AM $0.049 $0.055 risen by 13.40%
$17 Study results show new Sofra drug reduces inflammation 19 May 2023 8:19AM $0.048 $0.055 risen by 14.58%
$17 Innovative Sofra research presented at European event 18 May 2023 8:16AM $0.051 $0.055 risen by 7.84%
$17 Change of Director's Interest Notice - FB 10 May 2023 8:19AM $0.041 $0.055 risen by 34.15%
$17 Upcoming Expiry of Listed Options (ASX Code NOXO) 8 May 2023 8:54AM $0.054 $0.055 risen by 1.85%
$17 Change of Director's Interest Notice - FB 4 May 2023 5:00PM $0.048 $0.055 risen by 14.58%
$17 March 2023 Quarterly Activities Report and Appendix 4C 24 Apr 2023 8:38AM $0.069 $0.055 fallen by 20.29%
$17 Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs 6 Apr 2023 8:08AM $0.110 $0.055 fallen by 50%
$17 Noxopharm Announces Novel mRNA Vaccine Enhancer 28 Mar 2023 8:17AM $0.095 $0.055 fallen by 42.11%
$17 Appendix 4D and Half Year 2023 Financial Report 24 Feb 2023 1:24PM $0.105 $0.055 fallen by 47.62%
$17 Noxopharm to Present Sofra Study at LUPUS 2023 Conference 22 Feb 2023 8:07AM $0.110 $0.055 fallen by 50%
$17 December 2022 Quarterly Activities Report and Appendix 4C 27 Jan 2023 8:32AM $0.140 $0.055 fallen by 60.71%
$17 DARRT-2 Trial Efficacy Phase to Commence 17 Jan 2023 8:27AM $0.135 $0.055 fallen by 59.26%
$17 NOX Pipeline Boosted by $1.5M Grant to Hudson Institute 16 Dec 2022 8:20AM $0.145 $0.055 fallen by 62.07%
$17 Change of Director's Interest Notice - FB 15 Dec 2022 4:24PM $0.145 $0.055 fallen by 62.07%
$17 Notification of cessation of securities - NOX 15 Dec 2022 4:21PM $0.145 $0.055 fallen by 62.07%
$17 Federal Innovation Connections Grant Awarded 6 Dec 2022 8:52AM $0.165 $0.055 fallen by 66.67%
$17 IONIC Trial Progresses as Veyonda Passes Safety Milestone 2 Dec 2022 8:18AM $0.160 $0.055 fallen by 65.63%
$17 Notification of cessation of securities - NOX 21 Nov 2022 5:01PM $0.160 $0.055 fallen by 65.63%
$17 Constitution 17 Nov 2022 4:36PM $0.160 $0.055 fallen by 65.63%
$17 Results of Meeting 17 Nov 2022 4:32PM $0.160 $0.055 fallen by 65.63%
$17 Noxopharm 2022 AGM Corporate Presentation 17 Nov 2022 8:55AM $0.145 $0.055 fallen by 62.07%
$17 Noxopharm AGM 2022 Chair's Address 17 Nov 2022 8:53AM $0.145 $0.055 fallen by 62.07%

151 - 175 of 801 results

Page 7 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.